Depressive disorders: Processes leading to neurogeneration and potential novel treatments

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 80, Issue , 2018, Pages 189-204

  Brown, Gregory M ^a   McIntyre, Roger S ^a   Rosenblat, Joshua ^a   Hardeland, Rüdiger ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Chronotherapy; Cognition; Depression; Inflammation; Mechanisms; Neurodegeneration

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CURCUMIN; ICOSAPENTAENOIC ACID; INFLIXIMAB; MELATONIN; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; SIRUKUMAB;

BIPOLAR DEPRESSION; CIRCADIAN RHYTHM; COGNITIVE DEFECT; DEPRESSION; DRUG MEGADOSE; DRUG TARGETING; HUMAN; IMMUNOPATHOLOGY; LOW DRUG DOSE; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; COMPLICATION; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

COGNITIVE DYSFUNCTION; DEPRESSIVE DISORDER; HUMANS; MOLECULAR TARGETED THERAPY; NERVE DEGENERATION;

EID: 85018446860     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2017.04.023     Document Type: Review

References (317)

1. Aboul-Fotouh, S., Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol. Biochem. Behav. 104 (2013), 105–112, 10.1016/j.pbb.2012.12.027.
2. Al-Karawi, D., Jubair, L., Bright light therapy for nonseasonal depression: meta-analysis of clinical trials. J. Affect. Disord. 198 (2016), 64–71.
3. Albrecht, U., Circadian clocks and mood-related behaviors. [review]. Handb. Exp. Pharmacol. 217 (2013), 227–239.
4. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). fifth ed., 2013, American Psychiatric Association, Washington, DC.
5. Anderson, G., Berk, M., Dean, O., Moylan, S., Maes, M., Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 28 (2014), 1–10, 10.1007/s40263-013-0119-1.
6. Anonymous, Agomelatine: a review of adverse effects. Prescrire Int. 22 (2013), 70–71.
7. Arendt, J., Skene, D.J., Melatonin as a chronobiotic. Sleep Med. Rev. 9 (2005), 25–39.
8. Arendt, J., Skene, D.J., Middleton, B., Lockley, S.J., Deacon, S., Efficacy of melatonin treatment in jet lag, shift work, and blindness. J. Biol. Rhythm. 12 (1997), 604–617.
9. Atkinson, M., Kripke, D.F., Wolf, S.R., Autorhythmometry in manic-depressives. Chronobiologia 2 (1975), 325–335.
10. Bais, B., Kamperman, A.M., van der Zwaag, M.D., Dieleman, G.C., Harmsen van der Vliet-Torij, H.W., Bijma, H.H., Lieverse, R., Hoogendijk, W.J., Lambregtse-van den Berg, M.P., Bright light therapy in pregnant women with major depressive disorder: study protocol for a randomized, double-blind, controlled clinical trial. BMC Psychiatry, 16, 2016, 381.
11. Barbosa, I.G., Bauer, M.E., Machado-Vieira, R., Teixeira, A.L., Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast., 2014, 10.1155/2014/360481.
12. Barbosa, I.G., Machado-Vieira, R., Soares, J.C., Teixeira, A.L., The immunology of bipolar disorder. Neuroimmunomodulation 21 (2014), 117–122, 10.1159/000356539.
13. Barbosa, I.G., Rocha, N.P., Bauer, M.E., de Miranda, A.S., Huguet, R.B., Reis, H.J., Zunszain, P.A., Horowitz, M.A., Pariante, C.M., Teixeira, A.L., Chemokines in bipolar disorder: trait or state?. Eur. Arch. Psychiatry Clin. Neurosci. 263 (2013), 159–165, 10.1007/s00406-012-0327-6.
14. Barnard, A.R., Nolan, P.M., When clocks go bad: neurobehavioural conseuences of disrupted ccircadian timing. PLoS Genet. 4 (2008), 1–8.
15. Baron, K.G., Reid, K.J., Circadian misalignment and health. Int. Rev. Psychiatry 26 (2014), 139–154, 10.3109/09540261.2014.911149.
16. Bauer, I.E., Pascoe, M.C., Wollenhaupt-Aguiar, B., Kapczinski, F., Soares, J.C., Inflammatory mediators of cognitive impairment in bipolar disorder. J. Psychiatr. Res. 56 (2014), 18–27, 10.1016/j.jpsychires.2014.04.017.
17. Bechtel, W., Circadian rhythms and mood disorders: Are the phenomena and mechanisms causally related?. Front. Psychiatry, 6, 2015, 118.
18. Beck-Friis, J., Kjellman, B.F., Aperia, B., Unden, F., von Rosen, D., Ljunggren, J.G., Wetterberg, L., Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr. Scand. 71 (1985), 319–330.
19. Beck-Friis, J., Kjellman, B.F., Ljunggren, J.-G., Wetterberg, L., The pineal gland and melatonin in affective disorders. Brown, G.M., Wainwright, S.D., (eds.) The Pineal Gland: Endocrine Aspects, Advances in the Biosciences, 1984, Pergamon Press, Oxford, 313–325.
20. Beishuizen, A., Thijs, L.G., Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J. Endotoxin Res. 6 (2003), 3–24, 10.1179/096805103125001298.
21. Bellet, M.M., Orozco-Solis, R., Sahar, S., Eckel-Mahan, K., Sassone-Corsi, P., The time of metabolism: NAD +, SIRT1, and the circadian clock. Cold Spring Harb. Symp. Quant. Biol. 76 (2011), 31–38.
22. Bellivier, F., Geoffroy, P., Etain, B., Scott, J., Sleep- and circadian rhythm—associated pathways as therapeutic targets in bipolar disorder. Expert Opin. Ther. Targets 19 (2015), 747–763.
23. Benedetti, F., Dallaspezia, S., Colombo, C., Pirovano, A., Marino, E., Smeraldi, E., A length polymorphism in the circadian clock gene Per3 influences age at onset of bipolar disorder. Neurosci. Lett. 445 (2008), 184–187, 10.1016/j.neulet.2008.09.002.
24. Benedetti, F., Riccaboni, R., Locatelli, C., Poletti, S., Dallaspezia, S., Colombo, C., Rapid treatment response of suicidal symptoms to lithium, sleep deprivation, and light therapy (chronotherapeutics) in drug-resistant bipolar depression. J. Clin. Psychiatry 75 (2014), 133–140.
25. Bengesser, S.A., Reininghaus, E.Z., Lackner, N., Birner, A., Fellendorf, F.T., Platzer, M., Kainzbauer, N., Tropper, B., Hormanseder, C., Queissner, R., Kapfhammer, H.-P., Wallner-Liebmann, S.J., Fuchs, R., Petek, E., Windpassinger, C., Schnalzenberger, M., Reininghaus, B., Evert, B., Waha, A., Is the molecular clock ticking differently in bipolar disorder? Methylation analysis of the clock gene ARNTL. World J. Biol. Psychiatry 14 (2016), 1–9.
26. Bercik, P., The microbiota-gut-brain axis: learning from intestinal bacteria?. Gut 60 (2011), 288–289, 10.1136/gut.2010.226779.
27. Bergman, J., Miodownik, C., Bersudsky, Y., Sokolik, S., Lerner, P.P., Kreinin, A., Polakiewicz, J., Lerner, V., Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol. 36 (2013), 73–76, 10.1097/WNF.0b013e31828ef969.
28. Berk, M., Copolov, D.L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Bush, A.I., N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol. Psychiatry 64 (2008), 468–475, 10.1016/j.biopsych.2008.04.022.
29. Berk, M., Dean, O.M., Cotton, S.M., Gama, C.S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., Cobb, H., Bush, A.I., Dodd, S., Malhi, G.S., Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med., 10, 2012, 91, 10.1186/1741-7015-10-91.
30. Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yucel, M., Gama, C.S., Dodd, S., Dean, B., Magalhaes, P.V., Amminger, P., McGorry, P., Malhi, G.S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35 (2011), 804–817, 10.1016/j.neubiorev.2010.10.001.
31. Berson, D.M., Phototransduction in ganglion-cell photoreceptors. Pflügers Arch. 454 (2007), 849–855, 10.1007/s00424-007-0242-2.
32. Bezchlibnyk, Y.B., Wang, J.F., McQueen, G.M., Young, L.T., Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J. Neurochem. 79 (2001), 826–834.
33. Bilello, J.A., Thurmond, L.M., Smith, K.M., Pi, B., Rubin, R., Wright, S.M., Taub, F., Henry, M.E., Shelton, R.C., Papakostas, G.I., MDDScore: Confirmation of a blood test to aid in the diagnosis of major depressive disorder. J. Clin. Psychiatry 76 (2015), e199–e206, 10.4088/JCP.14m09029.
34. Black, C.N., Bot, M., Scheffer, P.G., Cuijpers, P., Penninx, B.W., Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 51 (2015), 164–175, 10.1016/j.psyneuen.2014.09.025.
35. Bloch, M.H., Hannestad, J., Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol. Psychiatry 17 (2012), 1272–1282, 10.1038/mp.2011.100.
36. Boivin, D.B., Influence of sleep-wake and circadian rhythm disturbances in psychatric disorders. J. Psychiatry Neurosci. 25 (2000), 446–458.
37. Bonmati-Carrion, M.A., Arguelles-Prieto, R., Martinez-Madrid, M.J., Reiter, R., Hardeland, R., Rol, M.A., Madrid, J.A., Protecting the melatonin rhythm through circadian healthy light exposure. Int. J. Mol. Sci. 15 (2014), 23448–23500, 10.3390/ijms151223448.
38. Bora, E., Harrison, B.J., Davey, C.G., Yücel, M., Pantelis, C., Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychol. Med. 42 (2012), 671–681, 10.1017/S0033291711001668.
39. Bourin, M., Prica, C., Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Curr. Pharm. Des., 15, 2009, 1675.
40. Bouwmans, M.E.J., Bos, E.H., Booij, S.H., van Faassen, M., Oldehinkel, A.J., de Jonge, P., Intra- and inter-individual variability of longitudinal daytime melatonin secretion patterns in depressed and non-depressed individuals. Chronobiol. Int. 32 (2015), 441–446, 10.3109/07420528.2014.973114.
41. Brietzke, E., Kauer-Sant'Anna, M., Teixeira, A.L., Kapczinski, F., Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 23 (2009), 1079–1082, 10.1016/j.bbi.2009.04.008.
42. Brietzke, E., Stertz, L., Fernandes, B.S., Kauer-Sant'anna, M., Mascarenhas, M., Escosteguy Vargas, A., Chies, J.A., Kapczinski, F., Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 116 (2009), 214–217, 10.1016/j.jad.2008.12.001.
43. Brown, R., Kocsis, J.H., Caroff, S., Amsterdam, J., Winokur, A., Stokes, P.E., Frazer, A., Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am. J. Psychiatry 142 (1985), 811–816.
44. Brusco, L.I., Fainstein, I., Marquez, M., Cardinali, D.P., Effect of melatonin in selected populations of sleep-disturbed patients. Biol. Signals Recept. 8 (1999), 126–131.
45. Brzezinski, A., Vangel, M.G., Wurtman, R.J., Norrie, G., Zhdanova, I., Ben-Shushan, A., Ford, I., Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med. Rev. 9 (2005), 41–50.
46. Bumb, J.M., Enning, F., Mueller, J.K., Van Der List, T., Rohleder, C., Findeisen, P., Noelte, I., Schwarz, E., Leweke, F.M., Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Compr. Psychiatry 68 (2016), 34–39, 10.1016/j.comppsych.2016.03.005.
47. Bunney, B., Li, J., Walsh, D., Stein, R., Vawter, M., Cartagena, P., Barchas, J., Schatzberg, A., Myers, R., Watson, S., Akil, H., Bunney, W., Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder HHS Public Access. Mol. Psychiatry 20138 (2015), 48–55, 10.1038/mp.2014.138.
48. Bunney, B.G., Bunney, W.E., Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. Biol. Psychiatry 73 (2013), 1164–1171, 10.1016/j.biopsych.2012.07.020.
49. Burkhart, K., Phelps, J.R., Amber lenses to block blue light and improve sleep: a randomized trial. Chronobiol. Int. 26 (2009), 1602–1612, 10.3109/07420520903523719.
50. Buzsáki, G., Watson, B.O., Brain rhythms and neural syntax: implications for efficient coding of cognitive content and neuropsychiatric disease. Dialogues Clin. Neurosci. 14 (2012), 345–367, 10.1097/ALN.0b013e318212ba87.
51. Byrne, E.M., Heath, A.C., Madden, P.A.F., Pergadia, M.L., Hickie, I.B., Montgomery, G.W., Martin, N.G., Wray, N.R., Testing the role of circadian genes in conferring risk for psychiatric disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 165 (2014), 254–260, 10.1002/ajmg.b.32230.
52. Capuron, L., Neurauter, G., Musselman, D.L., Lawson, D.H., Nemeroff, C.B., Fuchs, D., Miller, A.H., Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry 54 (2003), 906–914.
53. Carceller-Sindreu, M., de Diego-Adeliño, J., Serra-Blasco, M., Vives-Gilabert, Y., Martín-Blanco, A., Puigdemont, D., Álvarez, E., Pérez, V., Portella, M.J., Volumetric MRI study of the habenula in first episode, recurrent and chronic major depression. Eur. Neuropsychopharmacol. 25 (2015), 2015–2021, 10.1016/j.euroneuro.2015.08.009.
54. Cardinali, D.P., Brusco, L.I., Liberczuk, C., Furio, A.M., The use of melatonin in Alzheimer's disease. Neuroendocrinol. Lett. 23 (2002), 20–23.
55. Cardinali, D.P., Pandi-perumal, S.R., Brown, G.M., Sleep and circadian dysregulation in depressive illness pharmacological implications. Clin. Neuropsychiatry 8 (2011), 321–338.
56. Carroll, B.J., The dexamethasone suppression test for melancholia. Br. J. Psychiatry 140 (1982), 292–304.
57. Carvalho, A.F., Miskowiak, K.K., Hyphantis, T.N., Kohler, C.A., Alves, G.S., Bortolato, B., Sales, P.M., Machado-Vieira, R., Berk, M., McIntyre, R.S., Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol. Disord. Drug Targets 13 (2014), 1814–1835.
58. Chang, H.-C., Guarente, L., SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153 (2013), 1448–1460.
59. Chi, K.F., Korgaonkar, M., Grieve, S.M., Imaging predictors of remission to anti-depressant medications in major depressive disorder. J. Affect. Disord. 186 (2015), 134–144, 10.1016/j.jad.2015.07.002.
60. Choi, S., Han, K.M., Won, E., Yoon, B.J., Lee, M.S., Ham, B.J., Association of brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in the anterior corona radiata in major depression. J. Affect. Disord. 172 (2015), 74–80, 10.1016/j.jad.2014.09.042.
61. Claustrat, B., Brun, J., Chazot, G., The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 9 (2005), 11–24.
62. Corruble, E., de Bodinat, C., Belaïdi, C., Goodwin, G.M., Belaidi, C., Goodwin, G.M., Agomelatine Study Group, Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int. J. Neuropsychopharmacol. 16 (2013), 2219–2234, 10.1017/S1461145713000679.
63. Crowley, S.K., Youngstedt, S.D., Efficacy of light therapy for perinatal depression: a review. J. Physiol. Anthropol., 31, 2012, 15.
64. Cryan, J.F., Dinan, T.G., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. 13 (2012), 701–702, 10.1038/nrn3346.
65. Cutolo, M., Maestroni, G.J.M., The melatonin-cytokine connection in rheumatoid arthritis. Ann. Rheum. Dis. 64 (2005), 1109–1111.
66. Dallaspezia, S., Benedetti, F., Chronobiology of bipolar disorder: therapeutic implication. Curr. Psychiatry Rep. 17 (2015), 1–10, 10.1007/s11920-015-0606-9.
67. Dallaspezia, S., Benedetti, F., Chronobiological therapy for mood disorders. Expert. Rev. Neurother. 11 (2011), 961–970, 10.1586/ern.11.61.
68. Dallaspezia, S., Locatelli, C., Lorenzi, C., Pirovano, A., Colombo, C., Benedetti, F., Sleep homeostatic pressure and PER3 VNTR gene polymorphism influence antidepressant response to sleep deprivation in bipolar depression. J. Affect. Disord. 192 (2016), 64–69, 10.1016/j.jad.2015.11.039.
69. Dalton, E.J., Rotondi, D., Levitan, R.D., Kennedy, S.H., Brown, G.M., Use of slow-release melatonin in treatment-resistant depression. J. Psychiatry Neurosci. 25 (2000), 48–52.
70. Danilenko, K.V., Ivanova, I.A., Dawn simulation vs. bright light in seasonal affective disorder: Treatment effects and subjective preference. J. Affect. Disord. 180 (2015), 87–89.
71. Danilenko, K.V., Putilov, A.A., Melatonin treatment of winter depression following total sleep deprivation: waking EEG and mood correlates. Neuropsychopharmacology 30 (2005), 1345–1352.
72. Delavest, M., Even, C., Benjemaa, N., Poirier, M.-F., Jockers, R., Krebs, M.-O., Association of the intronic rs2072621 polymorphism of the X-linked GPR50 gene with affective disorder with seasonal pattern. Eur. Psychiatry 27 (2012), 369–371.
73. Delvecchio, G., Fossati, P., Boyer, P., Brambilla, P., Falkai, P., Gruber, O., Hietala, J., Lawrie, S.M., Martinot, J.L., McIntosh, A.M., Meisenzahl, E., Frangou, S., Common and distinct neural correlates of emotional processing in bipolar disorder and major depressive disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur. Neuropsychopharmacol. 22 (2012), 100–113, 10.1016/j.euroneuro.2011.07.003.
74. Demyttenaere, K., Agomelatine: a narrative review. Eur. Neuropsychopharmacol. 21:Suppl. 4 (2011), S703–S709, 10.1016/j.euroneuro.2011.07.004.
75. Depping, M.S., Wolf, N.D., Vasic, N., Sambataro, F., Thomann, P.A., Wolf, R.C., Common and distinct structural network abnormalities in major depressive disorder and borderline personality disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 65 (2016), 127–133, 10.1016/j.pnpbp.2015.09.007.
76. der Lek, R., Swaab, D.F., Twisk, J., Hol, E.M., Hoogendijk, W.J., Van Someren, E.J., Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. J. Am. Med. Assoc. 299 (2008), 2642–2655.
77. Dibner, C., Schibler, U., Albrecht, U., The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 72 (2010), 517–549, 10.1146/annurev-physiol-021909-135821.
78. Dolberg, O.T., Hirschmann, S., Grunhaus, L., Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry 155 (1998), 1119–1121.
79. Dolder, C.R., Nelson, M., Snider, M., Agomelatine treatment of major depressive disorder. Ann. Pharmacother. 42 (2008), 1822–1823.
80. Dowling, G.A., Burr, R.L., Van Someren, E.J., Hubbard, E.M., Luxenberg, J.S., Mastick, J., Cooper, B.A., Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J. Am. Geriatr. Soc. 56 (2008), 239–246.
81. Drago, A., Monti, B., Ronchi, D. De, Serretti, A., Giovanni, I.R.C.C.S.S., CRY1 variations impacts on the depressive relapse rate in a sample of bipolar patients. Psychiatry Investig. 12 (2015), 118–124.
82. Dridi, D., Zouiten, A., Mansour, H.Ben, Depression: chronophysiology and chronotherapy. Biol. Rhythm. Res. 45 (2014), 77–91.
83. Dunn, A.J., Swiergiel, A.H., de Beaurepaire, R., Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci. Biobehav. Rev. 29 (2005), 891–909, 10.1016/j.neubiorev.2005.03.023.
84. Dusi, N., Barlati, S., Vita, A., Brambilla, P., Brain structural effects of antidepressant treatment in major depression. Curr. Neuropharmacol. 13 (2015), 458–465, 10.2174/1570159X1304150831121909.
85. Ekdahl, C.T., Microglial activation - tuning and pruning adult neurogenesis. Front. Pharmacol., 3, 2012, 41, 10.3389/fphar.2012.00041.
86. Elder, G., Wetherell, M.A., Barclay, N.L., Ellis, J.G., The cortisol awakening response—applications and implications for sleep medicine. Sleep Med. Rev. 18 (2014), 215–224, 10.1016/j.smrv.2013.05.001.
87. Eniola, K., Bacigalupo, A., Mounsey, A., PURLs: light therapy for nonseasonal major depressive disorder?. J. Fam. Pract. 65 (2016), 486–488.
88. Eser, D., Baghai, T.C., Möller, H.-J., Evidence of agomelatine's antidepressant efficacy: The key points. Int. Clin. Psychopharmacol. 22:Suppl. 2 (2007), S15–S19.
89. Eser, D., Baghai, T.C., Möller, H.J., Agomelatine: the evidence for its place in the treatment of depression. Core Evid. 4 (2009), 171–179, 10.2147/CE.S6005.
90. Felger, J.C., Lotrich, F.E., Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246 (2013), 199–229, 10.1016/j.neuroscience.2013.04.060.
91. Fernandes, B.S., Steiner, J., Molendijk, M.L., Dodd, S., Nardin, P., Goncalves, C.A., Jacka, F., Kohler, C.A., Karmakar, C., Carvalho, A.F., Berk, M., C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 3 (2016), 1147–1156, 10.1016/S2215-0366(16)30370-4.
92. Flynn-Evans, E.E., Tabandeh, H., Skene, D.J., Lockley, S.W., Circadian rhythm disorders and melatonin production in 127 blind women with and without light perception. J. Biol. Rhythm. 29 (2014), 215–224.
93. Frazer, A., Brown, R., Kocsis, J., Caroff, S., Amsterdam, J., Winokur, A., Sweeney, J., Stokes, P., Patterns of melatonin rhythms in depression. J. Neural Transm. Suppl. 21 (1985), 269–290.
94. Frick, L.R., Williams, K., Pittenger, C., Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol., 2013, 10.1155/2013/608654.
95. Frodl, T., Amico, F., Is there an association between peripheral immune markers and structural/functional neuroimaging findings?. Prog. Neuropsychopharmacol. Biol. Psychiatry 48 (2014), 295–303, 10.1016/j.pnpbp.2012.12.013.
96. Gagné, A.-M., Lévesque, F., Gagné, P., Hébert, M., Impact of blue vs red light on retinal response of patients with seasonal affective disorder and healthy controls. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 (2011), 227–231.
97. Gahr, M., Freudenmann, R.W., Connemann, B.J., Hiemke, C., Schonfeldt-Lecuona, C., Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 46 (2013), 214–220, 10.1055/s-0033-1353156.
98. Galecki, P., Szemraj, J., Bartosz, G., Bienkiewicz, M., Galecka, E., Florkowski, A., Lewinski, A., Karbownik-Lewinska, M., Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J. Pineal Res. 48 (2010), 311–317, 10.1111/j.1600-079X.2010.00754.x.
99. Gill, R., Tsung, A., Billiar, T., Linking oxidative stress to inflammation: Toll-like receptors. Free Radic. Biol. Med. 48 (2010), 1121–1132, 10.1016/j.freeradbiomed.2010.01.006.
100. Goldsmith, D.R., Haroon, E., Woolwine, B.J., Jung, M.Y., Wommack, E.C., Harvey, P.D., Treadway, M.T., Felger, J.C., Miller, A.H., Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behav. Immun. 56 (2016), 281–288, 10.1016/j.bbi.2016.03.025.
101. Goldsmith, D.R., Rapaport, M.H., Miller, B.J., A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21 (2016), 1696–1709, 10.1038/mp.2016.3.
102. Gonzalez, R., Gonzalez, S., Villa, E., Ramirez, M., Zavala, J., Armas, R., Contreras, J., Dassori, A., Leach, R.J., Flores, D., Jerez, A., Raventós, H., Ontiveros, A., Nicolini, H., Escamilla, M., Identification of circadian gene variants in bipolar disorder in Latino populations. J. Affect. Disord. 186 (2015), 367–375, 10.1016/j.jad.2015.07.014.
103. Goodwin, G.M., Clinical studies on the efficacy of agomelatine on depressive symptoms. CNS Drugs 23:Suppl. 2 (2009), 35–39.
104. Gooley, J.J., Chamberlain, K., Smith, K.a., Khalsa, S.B.S., Rajaratnam, S.M.W., van Reen, E., Zeitzer, J.M., Czeisler, C.a., Lockley, S.W., Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J. Clin. Endocrinol. Metab. 96 (2011), 463–472, 10.1210/jc.2010-2098.
105. Gooley, J.J., Lu, J., Fischer, D., Saper, C.B., A broad role for melanopsin in nonvisual photoreception. J. Neurosci. 23 (2003), 7093–7106.
106. Gordijn, M.C.M., Mannetje, D't., Meesters, Y., The effects of blue-enriched light treatment compared to standard light treatment in Seasonal Affective Disorder. J. Affect. Disord. 136 (2012), 72–80.
107. Gottlieb, J.F., Terman, M., Outpatient triple chronotherapy for bipolar depression: case report. J. Psychiatr. Pract. 18 (2012), 373–380.
108. Gruz, F., Raffa, S., Santucci, C., Papale, R.M., Videla, M.G., Fernandez, M.G., Yantorno, S., Descalzi, V.I., Agomelatine: fulminant liver failure in a patient with fatty liver. Gastroenterol. Hepatol. 37 (2014), 92–94, 10.1016/j.gastrohep.2013.04.008.
109. Guaiana, G., Gupta, S., Chiodo, D., Davies, S.J., Haederle, K., Koesters, M., Agomelatine versus other antidepressive agents for major depression. Cochrane database Syst. Rev., 12, 2013, 10.1002/14651858.CD008851.pub2.
110. Guilleminault, C., Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive diorder. Eur. Neuropsychopharmacol., 15, 2005, S419.
111. Hack, L.M., Lockley, S.W., Arendt, J., Skene, D.J., The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. J. Biol. Rhythm. 18 (2003), 420–429.
112. Han, K.-M., Kim, D., Sim, Y., Kang, J., Kim, A., Won, E., Tae, W.-S., Ham, B.-J., Alterations in the brainstem volume of patients with major depressive disorder and their relationship with antidepressant treatment. J. Affect. Disord. 208 (2017), 68–75, 10.1016/j.jad.2016.08.066.
113. Hardeland, R., Melatonin and synthetic melatoninergic agonists in psychiatric and age-associated disorders: successful and unsuccessful approaches. Curr. Pharm. Des. 22 (2016), 1086–1100.
114. Hardeland, R., Melatonin, noncoding RNAs, messenger RNA stability and epigenetics—evidence, hints, gaps and perspectives. Int. J. Mol. Sci. 15 (2014), 18221–18252, 10.3390/ijms151018221.
115. Hardeland, R., Agomelatine and the risk of hepatotoxicity. J. Symptoms Signs 3 (2014), 341–346.
116. Hardeland, R., Melatonin in aging and disease ― multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 3:3 (2012), 194–225.
117. Hardeland, R., Rationale and Problems of Melatonergic Treatment. vol. 16, 2012, 7–14.
118. Hardeland, R., Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 35 (2009), 183–192, 10.1002/biof.23.
119. Hardeland, R., New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. Neuropsychiatr. Dis. Treat. 5 (2009), 341–354.
120. Hardeland, R., Cardinali, D.P., Brown, G.M., Pandi-Perumal, S.R., Melatonin and brain inflammaging. Prog. Neurobiol. 127–128 (2015), 46–63, 10.1016/j.pneurobio.2015.02.001.
121. Hardeland, R., Coto-Montes, A., Poeggeler, B., Circadian rhythms, oxidative stress and antioxidative defense mechanisms. Chronobiol. Int. 20 (2003), 921–962.
122. Harrisberger, F., Smieskova, R., Schmidt, A., Lenz, C., Walter, A., Wittfeld, K., Grabe, H.J., Lang, U.E., Fusar-Poli, P., Borgwardt, S., BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 55 (2015), 107–118, 10.1016/j.neubiorev.2015.04.017.
123. Harrison, J., Lam, R., Baune, B., McIntyre, R.S., Selection of cognitive tests for trials of therapeutic agents. Lancet Psychiatry, 3, 2016, 499.
124. Harrison, N.A., Brydon, L., Walker, C., Gray, M.A., Steptoe, A., Critchley, H.D., Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 66 (2009), 407–414, 10.1016/j.biopsych.2009.03.015.
125. Harry, G.J., Kraft, A.D., Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 33 (2012), 191–206, 10.1016/j.neuro.2012.01.012.
126. Hastings, M.H., Brancaccio, M., Maywood, E.S., Circadian pacemaking in cells and circuits of the suprachiasmatic nucleus. J. Neuroendocrinol. 26 (2014), 2–10, 10.1111/jne.12125.
127. Hastings, M.H., Goedert, M., Circadian clocks and neurodegenerative diseases: time to aggregate?. Curr. Opin. Neurobiol. 23 (2013), 880–887, 10.1016/j.conb.2013.05.004.
128. Henriksen, T.E., Skrede, S., Fasmer, O.B., Schoeyen, H., Leskauskaite, I., Bjørke-Bertheussen, J., Assmus, J., Hamre, B., Grønli, J., Lund, A., Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disord. 18 (2016), 221–232, 10.1111/bdi.12390.
129. Herbert, J., Cortisol and depression: three questions for psychiatry. Psychol. Med. 43 (2013), 449–469, 10.1017/S0033291712000955.
130. Howland, R.H., A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 34 (2011), 709–731, 10.2165/11593960-000000000-00000.
131. Howland, R.H., Publication bias and outcome reporting bias: agomelatine as a case example. J. Psychosoc. Nurs. Ment. Health Serv. 49:9 (2011), 11–14, 10.3928/02793695-20110809-01.
132. Hua, P., Liu, W., Chen, D., Zhao, Y., Chen, L., Zhang, N., Wang, C., Guo, S., Wang, L., Xiao, H., Kuo, S.H., Cry1 and Tef gene polymorphisms are associated with major depressive disorder in the Chinese population. J. Affect. Disord. 157 (2014), 100–103, 10.1016/j.jad.2013.11.019.
133. Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D.S., Quinn, K., Sanislow, C., Wang, P., Research Domain Criteria (RDoC): Toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167 (2010), 748–751, 10.1176/appi.ajp.2010.09091379.
134. Ivanov, S.V., Samushiya, M.A., Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study. Neuropsychiatr. Dis. Treat 10 (2014), 631–639, 10.2147/NDT.S58994.
135. Jaworska, N., Yang, X.-R., Knott, V., Macqueen, G., A review of fMRI studies during visual emotive processing in major depressive disorder. World J. Biol. Psychiatry 7321 (2014), 1–24, 10.3109/15622975.2014.885659.
136. Jaworska, N., Yücel, K., Courtright, A., Macmaster, F.P., Sembo, M., Macqueen, G., Subgenual anterior cingulate cortex and hippocampal volumes in depressed youth: the role of comorbidity and age. J. Affect. Disord. 190 (2016), 726–732, 10.1016/j.jad.2015.10.064.
137. Jimenez-Fernandez, S., Gurpegui, M., Diaz-Atienza, F., Perez-Costillas, L., Gerstenberg, M., Correll, C.U., Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. J. Clin. Investigation 76 (2015), 1658–1667, 10.4088/JCP.14r09179.
138. Jin, X., Shearman, L.P., Weaver, D.R., Zylka, M.J., de Vries, G.J., Reppert, S.M., A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 96 (1999), 57–68.
139. Johansson, C., Willeit, M., Smedh, C., Ekholm, J., Paunio, T., Kieseppä, T., Lichtermann, D., Praschak-Rieder, N., Neumeister, A., Nilsson, L.-G., Kasper, S., Peltonen, L., Adolfsson, R., Schalling, M., Partonen, T., Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 28 (2003), 734–739, 10.1038/sj.npp.1300121.
140. Jones, S.G., Benca, R.M., Circadian disruption in psychiatric disorders. Sleep Med. Clin. 10 (2015), 481–493, 10.1016/j.jsmc.2015.07.004.
141. Kalenderoglu, A., Çelik, M., Sevgi-Karadag, A., Egilmez, O.B., Optic coherence tomography shows inflammation and degeneration in major depressive disorder patients correlated with disease severity. J. Affect. Disord. 204 (2016), 159–165, 10.1016/j.jad.2016.06.039.
142. Kaltenboeck, A., Winkler, D., Kasper, S., Bipolar and related disorders in DSM-5 and ICD-10. CNS Spectr. 21 (2016), 318–323, 10.1017/S1092852916000079.
143. Kaminski-Hartenthaler, A., Nussbaumer, B., Forneris, C.A., Morgan, L.C., Gaynes, B.N., Sonis, J.H., Greenblatt, A. et al., Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst. Rev., 11, 2015.
144. Karim, A., Tolbert, D., Cao, C., Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J. Clin. Pharmacol. 46 (2006), 140–148.
145. Kasper, S., Corruble, E., Hale, A., Lemoine, P., Montgomery, S.A., Quera-Salva, M.A., Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int. Clin. Psychopharmacol. 28 (2013), 12–19, 10.1097/YIC.0b013e328359768e.
146. Kaufmann, F.N., Gazal, M., Bastos, C.R., Kaster, M.P., Ghisleni, G., Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Eur. J. Pharmacol. 76 (2015), 1658–1667, 10.1016/j.ejphar.2016.05.026.
147. Kayumov, L., Casper, R.F., Hawa, R.J., Perelman, B., Chung, S.A., Sokalsky, S., Shapiro, C.M., Blocking low-wavelength light prevents nocturnal melatonin suppression with no adverse effect on performance during simulated shift work. J. Clin. Endocrinol. Metab. 90 (2005), 2755–2761, 10.1210/jc.2004-2062.
148. Kayumov, L., Zhdanova, I.V., Shapiro, C.M., Melatonin, sleep, and circadian rhythm disorders. Semin. Clin. Neuropsychiatry 5 (2000), 44–55.
149. Keck, P.E. Jr., Mintz, J., McElroy, S.L., Freeman, M.P., Suppes, T., Frye, M.A., Altshuler, L.L., Kupka, R., Nolen, W.A., Leverich, G.S., Denicoff, K.D., Grunze, H., Duan, N., Post, R.M., Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol. Psychiatry 60 (2006), 1020–1022, 10.1016/j.biopsych.2006.03.056.
150. Kennedy, S.H., Agomelatine: Efficacy at each phase of antidepressant treatment. CNS Drugs 23:Suppl. 2 (2009), 41–47.
151. Kennedy, S.H., Eisfeld, B.S., Agomelatine and its therapeutic potential in the depressed patient. Neuropsychiatr. Dis. Treat. 3 (2007), 423–428.
152. Kennedy, S.H., Kutcher, S.P., Ralevski, E., Brown, G.M., Nocturnal melatonin and 24-hour 6-sulphatoxymelatonin levels in various phases of bipolar affective disorder. Psychiatry Res. 63 (1996), 219–222.
153. Kerestes, R., Davey, C.G., Stephanou, K., Whittle, S., Harrison, B.J., Clinical functional brain imaging studies of youth depression: a systematic review. NeuroImage Clin. 4 (2014), 209–231, 10.1016/j.nicl.2013.11.009.
154. Kessler, R.C., Petukhova, M., Sampson, N.A., Zaslavsky, A.M., Wittchen, H.-U., Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int. J. Methods Psychiatr. Res. 21 (2012), 169–184.
155. Khaleghipour, S., Masjedi, M., Ahade, H., Enayate, M., Pasha, G., Nadery, F., Ahmadzade, G., Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study. Sao Paulo Med. J. 130 (2012), 167–172, 10.1590/S1516-31802012000300006.
156. Kishi, T., Yoshimura, R., Kitajima, T., Okochi, T., Okumura, T., Tsunoka, T., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., Fukuo, Y., Naitoh, H., Umene-Nakano, W., Inada, T., Nakamura, J., Ozaki, N., Iwata, N., SIRT1 gene is associated with major depressive disorder in the Japanese population. J. Affect. Disord. 126 (2010), 167–173, 10.1016/j.jad.2010.04.003.
157. Koesters, M., Guaiana, G., Cipriani, A., Becker, T., Barbui, C., Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br. J. Psychiatry 203 (2013), 179–187, 10.1192/bjp.bp.112.120196.
158. Kohler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., Krogh, J., Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71 (2014), 1381–1391, 10.1001/jamapsychiatry.2014.1611.
159. Kraft, A.D., Harry, G.J., Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int. J. Environ. Res. Public Heal. 8 (2011), 2980–3018, 10.3390/ijerph8072980.
160. Kripke, D., Mullaney, D., Atkinson, M., Wolf, S., Circadian rhythm disorders in manic-depressives. Biol. Psychiatry 13 (1978), 335–351.
161. Kripke, D.F., Elliott, J.A., Welsh, D.K., Youngstedt, S.D., Photoperiodic and circadian bifurcation theories of depression and mania. F1000Res., 4, 2015, 107, 10.12688/f1000research.6444.1.
162. Kripke, D.F., Nievergelt, C.M., Joo, E., Shekhtman, T., Kelsoe, J.R., Circadian polymorphisms associated with affective disorders. J. Circadian Rhythms, 7, 2009, 2, 10.1186/1740-3391-7-2.
163. Lam, R.W., Berkowitz, A.L., Berga, S.L., Clark, C.M., Kripke, D.F., Gillin, J.C., Melatonin suppression in bipolar and unipolar mood disorders. Psychiatry Res. 33 (1990), 129–134.
164. Langan, J., Shajahan, P., Martin, D., Carleton, R., Agomelatine in unipolar depression in clinical practice: a retrospective chart review. Ther. Adv. Psychopharmacol. 1 (2011), 175–180.
165. Lavebratt, C., Sjöholm, L.K., Partonen, T., Schalling, M., Forsell, Y., PER2 variantion is associated with depression vulnerability. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153 (2010), 570–581, 10.1002/ajmg.b.31021.
166. Lavebratt, C., Sjöholm, L.K., Soronen, P., Paunio, T., Vawter, M.P., Bunney, W.E., Adolfsson, R., Forsell, Y., Wu, J.C., Kelsoe, J.R., Partonen, T., Schalling, M., CRY2 is associated with depression. PLoS One 5 (2010), 1–8.
167. Le-Niculescu, H., Patel, S.D., Bhat, M., Kuczenski, R., Faraone, S.V., Tsuang, M.T., McMahon, F.J., Schork, N.J., Nurnberger, J.I., Niculescu, A.B., Convergent functional genomics of genome-wide association data for bipolar disorder: Comprehensive identification of candidate genes, pathways and mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150 (2009), 155–181, 10.1002/ajmg.b.30887.
168. Lee, S.Y., Lee, S.J., Han, C., Patkar, A.A., Masand, P.S., Pae, C.U., Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 46 (2013), 224–235, 10.1016/j.pnpbp.2012.09.008.
169. Leheste, J.R., Torres, G., Resveratrol: brain effects on SIRT1, GPR50 and photoperiodic signaling. Front. Mol. Neurosci., 8, 2015, 61.
170. Leibenluft, E., Feldman-Naim, S., Turner, E.H., Wehr, T.A., Rosenthal, N.E., Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J. Clin. Psychiatry 58 (1997), 383–388.
171. Lener, M.S., Iosifescu, D.V., In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. Ann. N. Y. Acad. Sci. 1344 (2015), 50–65, 10.1111/nyas.12759.
172. Leppämäki, S., Partonen, T., Vakkuri, O., Lonnqvist, J., Partinen, M., Laudon, M., Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur. Neuropsychopharmacol. 13 (2003), 137–145.
173. Levoye, A., Dam, J., Ayoub, M.A., Guillaume, J.L., Couturier, C., Delagrange, P., Jockers, R., The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 25 (2006), 3012–3023.
174. Lewy, A.J., Clinical applications of melatonin in circadian disorders. Dialogues Clin. Neurosci. 5 (2003), 399–413.
175. Lewy, A.J., Ahmed, S., Jackson, J.M., Sack, R.L., Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol. Int. 9 (1992), 380–392.
176. Lewy, A.J., Bauer, V.K., Cutler, N.L., Sack, R.L., Melatonin treatment of winter depression: a pilot study. Psychiatry Res. 77 (1998), 57–61.
177. Lewy, A.J., Emens, J., Jackman, A., Yuhas, K., Circadian uses of melatonin in humans. Chronobiol. Int. 23 (2006), 403–412.
178. Lewy, A.J., Emens, J., Songer, J.B., Sims, N., Laurie, A.L., Fiala, S.C., Buti, A.L., Winter depression: integrating mood, circadian rhythms, and the sleep/wake and light/dark cycles into a bio-psycho-social-environmental model. Sleep Med. Clin. 4 (2009), 285–299.
179. Lewy, A.J., Emens, J.S., Lefler, B.J., Yuhas, K., Jackman, A.R., Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol. Int. 22 (2005), 1093–1106.
180. Lewy, A.J., Emens, J.S., Sack, R.L., Hasler, B.P., Bernert, R.A., Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol. Int. 19 (2002), 649–658.
181. Lewy, A.J., Nurnberger, J.I. Jr., Wehr, T.A., Pack, D., Becker, L.E., Powell, R.L., Newsome, D.A., Supersensitivity to light: possible trait marker for manic-depressive illness. Am. J. Psychiatry 142 (1985), 725–727.
182. Lewy, A.J., Sack, R.L., The dim light melatonin onset as a marker for circadian phase position. Chronobiol. Int. 6 (1989), 93–102.
183. Li, J.Z., Bunney, B.G., Meng, F., Hagenauer, M.H., Walsh, D.M., Vawter, M.P., Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. PNAS 110 (2013), 9950–9955, 10.1073/pnas.1305814110/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1305814110.
184. Liao, Y., Huang, X., Wu, Q., Yang, C., Kuang, W., Du, M., Lui, S., Yue, Q., Chan, R., Kemp, G., Gong, Q., Is depression a disconnection syndrome? Meta- analysis of diffusion tensor imaging studies in patients with MDD. J. Psychiatry Neurosci. 38 (2013), 49–56, 10.1503/jpn.110180.
185. Lindqvist, D., Mueller, S., Mellon, S.H., Su, Y., Epel, E.S., Reus, V.I., Rosser, R., Mahan, L., Scott Mackin, R., Yang, T.T., Wolkowitz, O.M., Peripheral antioxidant markers are associated with total hippocampal and CA3/dentate gyrus volume in MDD and healthy controls-preliminary findings. Psychiatry Res. Neuroimaging 224 (2014), 168–174, 10.1016/j.pscychresns.2014.09.002.
186. Liu, C., Chung, M., Genetics and epigenetics of circadian rhythms and their potential roles in neuropsychiatric disorders. Neurosci. Bull. 31 (2015), 141–159, 10.1007/s12264-014-1495-3.
187. Liu, H.C., Yang, Y.Y., Chou, Y.M., Chen, K.P., Shen, W.W., Leu, S.J., Immunologic variables in acute mania of bipolar disorder. J. Neuroimmunol. 150 (2004), 116–122, 10.1016/j.jneuroim.2004.01.006.
188. Liu, Y., Ho, R.C., Mak, A., Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J. Affect. Disord. 139 (2012), 230–239, 10.1016/j.jad.2011.08.003.
189. Lockley, S.W., Arendt, J., Skene, D.J., Visual impairment and circadian rhythm disorders. Dialogues Clin. Neurosci. 9 (2007), 301–314.
190. Lockley, S.W., Skene, D.J., James, K., Thapan, K., Wright, J., Arendt, J., Melatonin administration can entrain the free-running circadian system of blind subjects. J. Endocrinol. 164 (2000), R1–R6.
191. Lopresti, A.L., Drummond, P.D., Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J. Affect. Disord. 207 (2017), 188–196, 10.1016/j.jad.2016.09.047.
192. Lopresti, A.L., Maes, M., Maker, G.L., Hood, S.D., Drummond, P.D., Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord. 167 (2014), 368–375, 10.1016/j.jad.2014.06.001.
193. Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C., Castle, D., Mandell, J.W., Lee, K.S., Harris, T.H., Kipnis, J., Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341, 10.1038/nature14432.
194. Lowrey, P.L., Takahashi, J.S., Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu. Rev. Genomics Hum. Genet. 5 (2004), 407–441, 10.1146/annurev.genom.5.061903.175925.
195. Macintyre, D.J., McGhee, K.A., Maclean, A.W., Afzal, M., Briffa, K., Henry, B., Thomson, P.A., Muir, W.J., Blackwood, D.H., Association of GPR50, an X-linked orphan G protein-coupled receptor, and affective disorder in an independent sample of the Scottish population. Neurosci. Lett. 475 (2010), 169–173, 10.1016/j.neulet.2010.03.072.
196. MacIsaac, S.E., Carvalho, A.F., Cha, D.S., Mansur, R.B., McIntyre, R.S., The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin. Pharmacother. 15 (2014), 259–274, 10.1517/14656566.2014.862233.
197. Maestroni, G.J.M., Cardinali, D.P., Esquifino, A.I., Pandi-Perumal, S.R., Does melatonin play a disease-promoting role in rheumatoid arthritis?. J. Neuroimmunol. 158 (2005), 106–111.
198. Malykhin, N.V., Coupland, N.J., Hippocampal neuroplasticity in major depressive disorder. Neuroscience 309 (2015), 200–213, 10.1016/j.neuroscience.2015.04.047.
199. Mansour, H.A., Wood, J., Logue, T., Chowdari, K.V., Dayal, M., Kupfer, D.J., Monk, T.H., Devlin, B., Nimgaonkar, V.L., Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes. Brain. Behav. 5 (2006), 150–157, 10.1111/j.1601-183X.2005.00147.x.
200. Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., Di Giannantonio, M., Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J. Clin. Psychopharmacol. 32 (2012), 487–491, 10.1097/JCP.0b013e31825d6c25.
201. Martynhak, B.J., Pereira, M., de Souza, C.P., Andreatini, R., Stretch, shrink, and shatter the rhythms: the intrinsic circadian period in mania and depression. CNS Neurol. Disord. Drug Targets 14 (2015), 963–969.
202. Maurya, P.K., Noto, C., Rizzo, L.B., Rios, A.C., Nunes, S.O.V., Barbosa, D.S., Sethi, S., Zeni, M., Mansur, R.B., Maes, M., Brietzke, E., The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 65 (2016), 134–144, 10.1016/j.pnpbp.2015.08.016.
203. McClung, C.A., How might circadian rhythms control mood? Let me count the ways. Biol. Psychiatry 74 (2013), 242–249, 10.1016/j.biopsych.2013.02.019.
204. McIntyre, R.S., Cha, D.S., Soczynska, J.K., Woldeyohannes, H.O., Gallaugher, L.A., Kudlow, P., Alsuwaidan, M., Baskaran, A., Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress. Anxiety 30 (2013), 515–527, 10.1002/da.22063.
205. McIntyre, R.S., Lee, Y., Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI). Curr. Opin. Psychiatry 29 (2016), 48–55, 10.1097/YCO.0000000000000221.
206. McIntyre, R.S., Soczynska, J.Z., Woldeyohannes, H.O., Alsuwaidan, M.T., Cha, D.S., Carvalho, A.F., Jerrell, J.M., Dale, R.M., Gallaugher, L.A., Muzina, D.J., Kennedy, S.H., The impact of cognitive impairment on perceived workforce performance: results from the international mood disorders collaborative project. Compr. Psychiatry 56 (2015), 279–282, 10.1016/j.comppsych.2014.08.051.
207. McIntyre, R.S., Xiao, H.X., Syeda, K., Vinberg, M., Carvalho, A.F., Mansur, R.B., Maruschak, N., Cha, D.S., The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs 29 (2015), 577–589, 10.1007/s40263-015-0263-x.
208. McNamara, R.K., Lotrich, F.E., Elevated immune-inflammatory signaling in mood disorders: A new therapeutic target?. Expert. Rev. Neurother. 12 (2012), 1143–1161, 10.1586/ern.12.98.
209. Meesters, Y., Dekker, V., Schlangen, L.J.M., Bos, E.H., Ruiter, M.J., Low-intensity blue-enriched white light (750 lux) and standard bright light (10,000 lux) are equally effective in treating SAD. A randomized controlled study. BMC Psychiatry, 11, 2011, 17.
210. Meesters, Y., Winthorst, W.H., Duijzer, W.B., Hommes, V., The effects of low-intensity narrow-band blue-light treatment compared to bright white-light treatment in sub-syndromal seasonal affective disorder. BMC Psychiatry, 16, 2016, 27.
211. Millan, M.J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.M., Cussac, D., The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 306 (2003), 954–964.
212. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65 (2009), 732–741, 10.1016/j.biopsych.2008.11.029.
213. Mishima, K., Tozawa, T., Satoh, K., Matsumoto, Y., Hishikawa, Y., Okawa, M., Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol. Psychiatry 45 (1999), 417–421.
214. Modabbernia, A., Taslimi, S., Brietzke, E., Ashrafi, M., Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 24 (2013), 15–25, 10.1016/j.biopsych.2013.01.007.
215. Montastruc, F., Scotto, S., Vaz, I.R., Guerra, L.N., Escudero, A., Sainz, M., Falomir, T., Bagheri, H., Herdeiro, M.T., Venegoni, M., Montastruc, J.L., Carvajal, A., Sáinz, M., Falomir, T., Bagheri, H., Herdeiro, M.T., Venegoni, M., Montastruc, J.L., Carvajal, A., Hepatotoxicity related to agomelatine and other new antidepressants: a case/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems. J. Clin. Psychopharmacol. 34 (2014), 327–330, 10.1097/JCP.0000000000000094.
216. Moreira, J., Geoffroy, P.A., Lithium and bipolar disorder: impacts from molecular to behavioural circadian rhythms. Chronobiol. Int. 33 (2016), 35–373.
217. Moylan, S., Berk, M., Dean, O.M., Samuni, Y., Williams, L.J., O'Neil, A., Hayley, A.C., Pasco, J.A., Anderson, G., Jacka, F.N., Maes, M., Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav. Rev. 45 (2014), 46–62, 10.1016/j.neubiorev.2014.05.007.
218. Munkholm, K., Brauner, J.V., Kessing, L.V., Vinberg, M., Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 47 (2013), 1119–1133, 10.1016/j.jpsychires.2013.05.018.
219. Munkholm, K., Vinberg, M., Kessing, L.V., Cytokines in bipolar disorder: a systematic review and meta-analysis. J. Affect. Disord. 144 (2013), 16–27, 10.1016/j.jad.2012.06.010.
220. Munkholm, K., Weikop, P., Kessing, L.V., Vinberg, M., Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav. Immun. 43 (2015), 205–213, 10.1016/j.bbi.2014.09.021.
221. Murphy, M.L., Frodl, T., Meta-analysis of diffusion tensor imaging studies shows altered fractional anisotropy occurring in distinct brain areas in association with depression. Biol. Mood Anxiety Disord., 1, 2011, 3.
222. Naismith, S.L., Hermens, D.F., Ip, T.K.C., Bolitho, S., Scott, E., Rogers, N.L., Hickie, I.B., Circadian profiles in young people during the early stages of affective disorder. Transl. Psychiatry, 2, 2012, e123, 10.1038/tp.2012.47.
223. Nakahata, Y., Kaluzova, M., Grimaldi, B., Sahar, S., Hirayama, J., Chen, D., Guarente, L.P., Sassone-Corsi, P., The NAD +-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 134 (2008), 329–340.
224. Nathan, P.J., Burrows, G.D., Norman, T.R., Melatonin sensitivity to dim white light in affective disorders. Neuropsychopharmacology 21 (1999), 408–413.
225. Nechita, F., Pirlog, M.-C., Chiriţă, A.L., Circadian malfunctions in depression - neurobiological and psychosocial approaches. [review]. Romanian J. Morphol. Embryol. 56 (2015), 949–955.
226. Nemeroff, C.B., Weinberger, D., Rutter, M., MacMillan, H.L., Bryant, R.A., Wessely, S., Stein, D.J., Pariante, C.M., Seemüller, F., Berk, M., Malhi, S., Preisig, M., Brüne, M., Lysaker, P., Forum. Current controversires in psychiatry: DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions. BMC Med. 11 (2013), 1–19.
227. Nicolaides, N.C., Charmandari, E., Chrousos, G.P., Kino, T., Circadian endocrine rhythms: The hypothalamic-pituitary-adrenal axis and its actions. Ann. N. Y. Acad. Sci. 1318 (2014), 71–80, 10.1111/nyas.12464.
228. Nievergelt, C.M., Kripke, D.F., Barrett, T.B., Burg, E., Remick, R.A., Sadovnick, A.D., McElroy, S.L., Keck, P.E. Jr., Schork, N.J., Kelsoe, J.R., Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B (2006), 234–241, 10.1002/ajmg.b.30252.
229. Nussbaumer, B., Kaminski-Hartenthaler, A., Forneris, C.A., Morgan, L.C., Sonis, J.H., Gaynes, B.N., Greenblatt, A., Wipplinger, J., Lux, L.J., Winkler, D., Van Noord, M.G., Hofmann, J., Gartiehner, G., Light therapy for preventing seasonal affective disorder. Cochrane Database Syst. Rev., 11, 2015.
230. O'Connor, S., Agius, M., A systematic review of structural and functional MRI differences between psychotic and nonpsychotic depression. Psychiatr. Danub. 27 (2015), S235–S239, 10.1016/S0924-9338(14)78463-9.
231. Oldham, M.A., Ciraulo, D.A., Bright light therapy for depression: a review of its effects on chronobiology and the autonomic nervous system. Chronobiol. Int. 31 (2014), 305–319.
232. Owen, R.T., Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 45 (2009), 599–608.
233. Pace, T.W., Miller, A.H., Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci. 1179 (2009), 86–105, 10.1111/j.1749-6632.2009.04984.x.
234. Pail, G., Huf, W., Pjrek, E., Winkler, D., Willeit, M., Praschak-Rieder, N., Kasper, S., Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 64 (2011), 152–162.
235. Palta, P., Samuel, L.J., Miller, E.R. 3rd, Szanton, S.L., Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom. Med. 76 (2014), 12–19, 10.1097/PSY.0000000000000009.
236. Pandi-Perumal, S.R., Trakht, I., Srinivasan, V., Spence, D.W., Poeggeler, B., Hardeland, R., Cardinali, D.P., The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J. Biol. Psychiatry 10 (2009), 342–354.
237. Papakostas, G.I., Shelton, R.C., Henry, M.E., Bilello, J.A., Letters to the Editor. J. Clin. Psychiatry, 76, 2015, e1038, 10.1176/appi.ajp.2015.15060750.
238. Partonen, T., Circadian clock proteins in mood regulation. Front. Psychiatry, 5, 2014, 195.
239. Partonen, T., Treutlein, J., Alpman, A., Frank, J., Johansson, C., Depner, M., Aron, L., Rietschel, M., Wellek, S., Soronen, P., Paunio, T., Koch, A., Chen, P., Lathrop, M., Adolfsson, R., Persson, M.L., Kasper, S., Schalling, M., Peltonen, L., Schumann, G., Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann. Med. 39 (2007), 229–238.
240. Penders, T.M., Stanciu, C.N., Schoemann, A.M., Ninan, P.T., Bloch, R., Saeed, S.A., Bright light therapy as augmentation of pharmacotherapy for treatment of depression: a systematic review and meta-analysis. Prim. Care Companion CNS Disord., 18, 2016, 10.4088/PCC.15r01906.
241. Prasko, J., Bright light therapy. Neuroendocrinol. Lett. 29 (2008), 33–64.
242. Price, J.L., Drevets, W.C., Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn. Sci. 16 (2012), 61–71, 10.1016/j.tics.2011.12.011.
243. Price, J.L., Drevets, W.C., Neurocircuitry of mood disorders. Neuropsychopharmacology 35 (2010), 192–216, 10.1038/npp.2009.104.
244. Qin, J., Shen, H., Zeng, L.-L., Jiang, W., Liu, L., Hu, D., Predicting clinical responses in major depression using intrinsic functional connectivity. Neuroreport 26 (2015), 675–680, 10.1097/WNR.0000000000000407.
245. Racagni, G., Riva, M.A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., Tardito, D., Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J. Biol. Psychiatry 12 (2011), 574–587, 10.3109/15622975.2011.595823.
246. Rahman, S.A., Shapiro, C.M., Wang, F., Ainlay, H., Kazmi, S., Brown, T.J., Casper, R.F., Effects of filtering visual short wavelengths during nocturnal shiftwork on sleep and performance. Chronobiol. Int. 30 (2013), 951–962, 10.3109/07420528.2013.789894.
247. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41, 10.1001/2013.jamapsychiatry.4.
248. Rajendran, B., Janakarajan, V.N., Circadian clock gene aryl hydrocarbon receptor nuclear translocator-like polymorphisms are associated with seasonal affective disorder: an Indian family study. Indian J. Psychiatry 58 (2016), 57–60.
249. Rao, J.S., Harry, G.J., Rapoport, S.I., Kim, H.W., Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 15 (2010), 384–392, 10.1038/mp.2009.47.
250. Rapaport, M.H., Nierenberg, A.A., Schettler, P.J., Kinkead, B., Cardoos, A., Walker, R., Mischoulon, D., Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol. Psychiatry 21 (2016), 71–79, 10.1038/mp.2015.22.
251. Rastad, C., Ulfberg, J., Lindberg, P., Improvement in fatigue, sleepiness, and health-related quality of life with bright light treatment in persons with seasonal affective disorder and subsyndromal SAD. Depress. Res. Treat., 2011, 10.1155/2011/543906.
252. Robertson, J.M., Tanguay, P.E., Case study: the use of melatonin in a boy with refractory bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 36 (1997), 822–825.
253. Rock, P.L., Roiser, J.P., Riedel, W.J., Blackwell, A.D., Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 44 (2014), 2029–2040, 10.1017/S0033291713002535.
254. Roiser, J.P., Sahakian, B.J., Hot and cold cognition in depression. CNS Spectr. 18 (2013), 139–149, 10.1017/S1092852913000072.
255. Rosenblat, J.D., Brietzke, E., Mansur, R.B., Maruschak, N.A., Lee, Y., McIntyre, R.S., Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: evidence, pathophysiology and treatment implications. J. Affect. Disord. 188 (2015), 149–159, 10.1016/j.jad.2015.08.058.
256. Rosenblat, J.D., Cha, D.S., Mansur, R.B., McIntyre, R.S., Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 53 (2014), 23–34, 10.1016/j.pnpbp.2014.01.013.
257. Rosenblat, J.D., Gregory, J.M., McIntyre, R.S., Pharmacologic implications of inflammatory comorbidity in bipolar disorder. Curr. Opin. Pharmacol. 29 (2016), 63–69, 10.1016/j.coph.2016.06.007.
258. Rosenblat, J.D., McIntyre, R.S., Bipolar disorder and inflammation. Psychiatr. Clin. N. Am. 39 (2016), 125–137, 10.1016/j.psc.2015.09.006.
259. Rothschild, A.J., A blood test for depression?. J. Clin. Psychiatry 76 (2015), e218–e219, 10.4088/JCP.14com09515.
260. Rubin, R.T., Heist, E.K., McGeoy, S.S., Hanada, K., Lesser, I.M., Neuroendocrine aspects of primary endogenous depression. XI. Serum melatonin measures in patients and matched control subjects. Arch. Gen. Psychiatry 49 (1992), 558–567.
261. Sachar, E.J., Hellman, L., Roffwarg, H.P., Halpern, F.S., Fukushima, D.K., Gallagher, T.F., Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch. Gen. Psychiatry 28 (1973), 19–24.
262. Sanmukhani, J., Satodia, V., Trivedi, J., Patel, T., Tiwari, D., Panchal, B., Goel, A., Tripathi, C.B., Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother. Res. 28 (2014), 579–585, 10.1002/ptr.5025.
263. Sarris, J., Mischoulon, D., Schweitzer, I., Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J. Clin. Psychiatry 73 (2012), 81–86, 10.4088/JCP.10r06710.
264. Sasseville, A., Benhaberou-Brun, D., Fontaine, C., Charon, M.-C., Hebert, M., Wearing blue-blockers in the morning could improve sleep of workers on a permanent night schedule: a pilot study. Chronobiol. Int. 26 (2009), 913–925, 10.1080/07420520903044398.
265. Sasseville, A., Hébert, M., Using blue-green light at night and blue-blockers during the day to improves adaptation to night work: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 34 (2010), 1236–1242, 10.1016/j.pnpbp.2010.06.027.
266. Sasseville, A., Paquet, N., Sévigny, J., Hébert, M., Blue blocker glasses impede the capacity of bright light to suppress melatonin production. J. Pineal Res. 41 (2006), 73–78, 10.1111/j.1600-079X.2006.00332.x.
267. Saus, E., Soria, V., Escaramís, G., Vivarelli, F., Crespo, J.M., Kagerbauer, B., Menchòn, J.M., Urretavizcaya, M., Gratacòs, M., Estivill, X., Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum. Mol. Genet. 19 (2010), 4017–4025, 10.1093/hmg/ddq316.
268. Saxvig, I.W., Wilhelmsen-Langeland, A., Pallesen, S., Vedaa, Ø., Nordhus, I.-H., Bjorvatn, B., A randomized controlled trial with bright light and melatonin for delayed sleep phase disorder: effects on subjective and objective sleep. Chronobiol. Int. 31 (2014), 72–86.
269. Schnell, A., Albrecht, U., Sandrelli, F., Rhythm and mood: relationships between the circadian clock and mood-related behavior. Behav. Neurosci. 128 (2014), 326–343, 10.1037/a0035883.
270. Schwartz, R.S., Olds, J., The psychiatry of light. Harv. Rev. Psychiatry 23 (2015), 188–194.
271. Serfaty, M.A., Osborne, D., Buszewicz, M.J., Blizard, R., Raven, P.W., A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int. Clin. Psychopharmacol. 25 (2010), 132–142.
272. Setiawan, E., Wilson, A.A., Mizrahi, R., Rusjan, P.M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J.L., Rekkas, P.V., Houle, S., Meyer, J.H., Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72 (2015), 268–275, 10.1001/jamapsychiatry.2014.2427.
273. Sexton, C.E., Mackay, C.E., Ebmeier, K.P., A systematic review of diffusion tensor imaging studies in affective disorders. Biol. Psychiatry 66 (2009), 814–823, 10.1016/j.biopsych.2009.05.024.
274. Sexton, C.E., MacKay, C.E., Ebmeier, K.P., A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. Am. J. Geriatr. Psychiatry 21 (2013), 184–195, 10.1016/j.jagp.2012.10.019.
275. Shearman, L.P., Sriram, S., Weaver, D.R., Maywood, E.S., Chaves, I., Zheng, B., Kume, K., Lee, C.C., van der Horst, G.T., Hastings, M.H., Reppert, S.M., Interacting molecular loops in the mammalian circadian clock. Science 288 (2000), 1013–1019, 10.1126/science.288.5468.1013.
276. Shi, S.Q., White, M.J., Borsetti, H.M., Pendergast, J.S., Hida, A., Ciarleglio, C.M., de Verteuil, P.A., Cadar, A.G., Cala, C., McMahon, D.G., Shelton, R.C., Williams, S.M., Johnson, C.H., Molecular analyses of circadian gene variants reveal sex-dependent links between depression and clocks. Transl. Psychiatry, 6, 2016, e748, 10.1038/tp.2016.9.
277. Singer, C., Tractenberg, R.E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., Thal, L.J., A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26 (2003), 893–901.
278. Singh, S.P., Singh, V., Kar, N., Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int. J. Neuropsychopharmacol. 15 (2012), 417–428.
279. Sjöholm, L.K., Backlund, L., Cheteh, E.H., Ek, I.R., Frisén, L., Schalling, M., Ösby, U., Lavebratt, C., Nikamo, P., CRY2 is associated with rapid cycling in bipolar disorderpatients. PLoS One 5 (2010), 1–6, 10.1371/journal.pone.0012632.
280. Skene, D.J., Optimization of light and melatonin to phase-shift human circadian rhythms. J. Neuroendocrinol. 15 (2003), 438–441.
281. Skene, D.J., Deacon, S., Arendt, J., Use of melatonin in circadian rhythm disorders and following phase shifts. Acta Neurobiol. Exp. (Wars) 56 (1996), 359–362.
282. Smith, M.R., Eastman, C.I., Phase delaying the human circadian clock with blue-enriched polychromatic light. Chronobiol. Int. 26 (2009), 709–725, 10.1080/07420520902927742.
283. Smith, M.R., Revell, V.L., Eastman, C.I., Phase advancing the human circadian clock with blue-enriched polychromatic light. Sleep Med. 10 (2009), 287–294.
284. Soria, V., Martinez-Amoros, E., Escaramis, G., Valero, J., Crespo, J.M., Gutierrez-Zotes, A., Bayes, M., Martorell, L., Vilella, E., Estivill, X., Menchon, J.M., Gratacos, M., Urretavizcaya, M., Resequencing and association analysis of arylalkylamine N-acetyltransferase (AANAT) gene and its contribution to major depression susceptibility. J. Pineal Res. 49 (2010), 35–44, 10.1111/j.1600-079X.2010.00763.x.
285. Soria, V., Martínez-Amorós, E., Escaramís, G., Valero, J., Pérez-Egea, R., García, C., Gutiérrez-Zotes, A., Puigdemont, D., Bayés, M., Crespo, J.M., Martorell, L., Vilella, E., Labad, A., Vallejo, J., Pérez, V., Menchón, J.M., Estivill, X., Gratacòs, M., Urretavizcaya, M., Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 35 (2010), 1279–1289, 10.1038/npp.2009.230.
286. Soria, V., Urretavizcaya, M., Circadian rhythms and depression. Actas Españolas Psiquiatr. 37 (2009), 222–232.
287. Souetre, E., Salvati, E., Belugou, J.L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.L., Darcourt, G., Souêtre, E., Salvati, E., Belugou, J.L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.L., Darcourt, G., Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res. 28 (1989), 263–278, 10.1016/0165-1781(89)90207-2.
288. Srinivasan, V., Pandi-Perumal, S.R., Cardinali, D.P., Poeggeler, B., Hardeland, R., Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav. Brain Funct., 2, 2006, 15.
289. Srinivasan, V., Pandi-Perumal, S.R., Trahkt, I., Spence, D.W., Poeggeler, B.H., Hardeland, R., Cardinali, D.P., Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int. J. Neurosci. 119 (2009), 821–846.
290. Srinivasan, V., Pandi-Perumal, S.R., Trakht, I., Spence, D.W., Hardeland, R., Poeggeler, B., Cardinali, D.P., Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res. 165 (2009), 201–214.
291. Stertz, L., Magalhaes, P.V., Kapczinski, F., Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr. Opin. Psychiatry 26 (2013), 19–26, 10.1097/YCO.0b013e32835aa4b4.
292. Stewart, J.W., Halbreich, U., Plasma melatonin levels in depressed patients before and after treatment with antidepressant medication. Biol. Psychiatry 25 (1989), 33–38.
293. Stratmann, M., Konrad, C., Kugel, H., Krug, A., Schöning, S., Ohrmann, P., Uhlmann, C., Postert, C., Suslow, T., Heindel, W., Arolt, V., Kircher, T., Dannlowski, U., Insular and hippocampal gray matter volume reductions in patients with major depressive disorder. PLoS One, 9, 2014, 10.1371/journal.pone.0102692.
294. Suzuki, M., Dallaspezia, S., Locatelli, C., Uchiyama, M., Colombo, C., Benedetti, F., Discrepancy between subjective and objective severity as a predictor of response to chronotherapeutics in bipolar depression. J. Affect. Disord. 204 (2016), 48–53.
295. Swardfager, W., Rosenblat, J.D., Benlamri, M., McIntyre, R.S., Mapping inflammation onto mood: inflammatory mediators of anhedonia. Neurosci. Biobehav. Rev. 64 (2016), 148–166, 10.1016/j.neubiorev.2016.02.017.
296. Taylor, D., Sparshatt, A., Varma, S., Olofinjana, O., Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ, 348, 2014, g1888, 10.1136/bmj.g1888.
297. Terman, M., Terman, J.S., Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. Am. J. Psychiatry 163 (2006), 2126–2133.
298. Thompson, C., Franey, C., Arendt, J., Checkley, S.A., A comparison of melatonin secretion in depressed patients and normal subjects. Br. J. Psychiatry 152 (1988), 260–265.
299. Thomson, P.A., Wray, N.R., Thomson, A.M., Dunbar, D.R., Grassie, M.A., Condie, A., Walker, M.T., Smith, D.J., Pulford, D.J., Muir, W., Blackwood, D.H., Porteous, D.J., Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol. Psychiatry 10 (2005), 470–478.
300. Turnbull, A.V., Rivier, C.L., Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol. Rev. 79 (1999), 1–71.
301. Tuunainen, A., Kripke, D.F., Endo, T., Light therapy for non-seasonal depression. Cochrane Database Syst. Rev., 2004, CD004050, 10.1002/14651858.CD004050.pub2.
302. Tymofiyeva, O., Connolly, C.G., Ho, T.C., Sacchet, M.D., Henje Blom, E., LeWinn, K.Z., Xu, D., Yang, T.T., DTI-based connectome analysis of adolescents with major depressive disorder reveals hypoconnectivity of the right caudate. J. Affect. Disord. 207 (2017), 18–25, 10.1016/j.jad.2016.09.013.
303. Uher, R., Payne, J.L., Pavlova, B., Perlis, R.H., Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress. Anxiety 31 (2014), 459–471, 10.1002/da.22217.
304. van der Lely, S., Frey, S., Garbazza, C., Wirz-Justice, A., Jenni, O.G., Steiner, R., Wolf, S., Cajochen, C., Bromundt, V., Schmidt, C., Blue blocker glasses as a countermeasure for alerting effects of evening light-emitting diode screen exposure in male teenagers. J. Adolesc. Health 56 (2015), 113–119, 10.1016/j.jadohealth.2014.08.002.
305. Videnovic, A., Lazar, A.S., Barker, R.A., Overeem, S., “The clocks that time us”—circadian rhythms in neurodegenerative disorders. Nat. Rev. Neurol. 10 (2014), 683–693.
306. Voican, C.S., Corruble, E., Naveau, S., Perlemuter, G., Antidepressant-induced liver injury: a review for clinicians. Am. J. Psychiatry 171 (2014), 404–415, 10.1176/appi.ajp.2013.13050709.
307. Vreeburg, S.A., Hoogendijk, W.J., van Pelt, J., Verhagen, J.C., van Dyck, R., Smit, J.H., Zitman, F.G., Penninx, B.W., Major depressive disorder and hypothalamic-pituitary-adrenal Axis activity. Arch. Gen. Psychiatry 66 (2009), 617–626.
308. Vrshek-Schallhorn, S., Doane, L.D., Mineka, S., Zinbarg, R.E., Craske, M.G., Adam, E.K., The cortisol awakening response predicts major depression: predictive stability over a 4-year follow-up and effect of depression history. Psychol. Med. 43 (2013), 483–493, 10.1017/S0033291712001213.
309. Wang, J., Dunn, A.J., Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem. Int. 33 (1998), 143–154.
310. Wessa, M., Lois, G., Brain functional effects of psychopharmacological treatment in major depression: a focus on neural circuitry of affective processing. Curr. Neuropharmacol. 13 (2015), 466–479, 10.2174/1570159X13666150416224801.
311. Whalley, L.J., Perini, T., Shering, A., Bennie, J., Melatonin response to bright light in recovered, drug-free, bipolar patients. Psychiatry Res. 38 (1991), 13–19.
312. Wilhelmsen-Langeland, A., Saxvig, I.W., Pallesen, S., Nordhus, I.-H., Vedaa, Ø., Lundervold, A.J., Bjorvatn, B., A randomized controlled trial with bright light and melatonin for the treatment of delayed sleep phase disorder: effects on subjective and objective sleepiness and cognitive function. J. Biol. Rhythm. 28 (2013), 306–321.
313. Wright, C.E., Strike, P.C., Brydon, L., Steptoe, A., Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav. Immun. 19 (2005), 345–350, 10.1016/j.bbi.2004.10.003.
314. Wu, J.C., Kelsoe, J.R., Schachat, C., Bunney, B.G., DeModena, A., Golshan, S., Gillin, J.C., Potkin, S.G., Bunney, W.E., Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol. Psychiatry 66 (2009), 298–301.
315. Young, J.J., Bruno, D., Pomara, N., A review of the relationship between proinflammatory cytokines and major depressive disorder. J. Affect. Disord. 169 (2014), 15–20, 10.1016/j.jad.2014.07.032.
316. Zawilska, J.B., Skene, D.J., Arendt, J., Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol. Rep. 61 (2009), 383–410.
317. Zhang, J., Terreni, L., De Simoni, M.G., Dunn, A.J., Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem. Int. 38 (2001), 303–308.